tbuckley/cabot-search huggingface dataset:
Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic Pain
Authors: Sanket S. Dhruva, Jaime Murillo, Omid Ameli, Pamela E. Morin, Donna L. Spencer, Rita F. Redberg, Ken Cohen
Journal: JAMA Neurology (2022)

Spinal cord stimulators (SCSs) are increasingly used for the treatment of chronic pain. There is a need for studies with long-term follow-up.To determine the comparative effectiveness and costs of SCSs compared with conventional medical management (CMM) in a large cohort of patients with chronic pain.This was a 1:5 propensity-matched retrospective comparative effectiveness research analysis of insured individuals from April 1, 2016, to August 31, 2018. This study used administrative claims data, including longitudinal medical and pharmacy claims, from US commercial and Medicare Advantage enrollees 18 years or older in Optum Labs Data Warehouse. Patients with incident diagnosis codes for failed back surgery syndrome, complex regional pain syndrome, chronic pain syndrome, and other chronic postsurgical back and extremity pain were included in this study. Data were analyzed from February 1, 2021, to August 31, 2022.SCSs or CMM.Surrogate measures for primary chronic pain treatment modalities, including pharmacologic and nonpharmacologic pain interventions (epidural and facet corticosteroid injections, radiofrequency ablation, and spine surgery), as well as total costs.In the propensity-matched population of 7560 patients, mean (SD) age was 63.5 (12.5) years, 3080 (40.7%) were male, and 4480 (59.3%) were female. Among matched patients, during the first 12 months, patients treated with SCSs had higher odds of chronic opioid use (adjusted odds ratio [aOR], 1.14; 95% CI, 1.01-1.29) compared with patients treated with CMM but lower odds of epidural and facet corticosteroid injections (aOR, 0.44; 95% CI, 0.39-0.51), radiofrequency ablation (aOR, 0.57; 95% CI, 0.44-0.72), and spine surgery (aOR, 0.72; 95% CI, 0.61-0.85). During months 13 to 24, there was no significant difference in chronic opioid use (aOR, 1.06; 95% CI, 0.94-1.20), epidural and facet corticosteroid injections (aOR, 1.00; 95% CI, 0.87-1.14), radiofrequency ablation (aOR, 0.84; 95% CI, 0.66-1.09), or spine surgery (aOR, 0.91; 95% CI, 0.75-1.09) with SCS use compared with CMM. Overall, 226 of 1260 patients (17.9%) treated with SCS experienced SCS-related complications within 2 years, and 279 of 1260 patients (22.1%) had device revisions and/or removals, which were not always for complications. Total costs of care in the first year were $39 000 higher with SCS than CMM and similar between SCS and CMM in the second year.In this large, real-world, comparative effectiveness research study comparing SCS and CMM for chronic pain, SCS placement was not associated with a reduction in opioid use or nonpharmacologic pain interventions at 2 years. SCS was associated with higher costs, and SCS-related complications were common.
Empirically supported affirmative psychological interventions for transgender and non-binary youth and adults: A systematic review
Authors: Pablo Expósito-Campos, José Ignacio Pérez-Fernández, Karmele Salaberria
Journal: Clinical Psychology Review (2022)

Research suggests that transgender and non-binary (TGNB) individuals experience lower levels of psychological well-being than the general population. Although practice recommendations and guidelines exist, there is a paucity of studies evaluating the effects of psychological interventions on this group. This systematic review aimed to synthesize and analyze existing empirical affirmative psychological interventions for TGNB individuals to assess their efficacy. Eight databases (PubMed, Web of Science, PsycINFO, Scopus, LILACS, Cochrane, ProQuest, Google Scholar) were searched from January 2010 to June 2022 to identify relevant studies. Included studies needed to be randomized controlled trials, quasi-experimental, or uncontrolled pre-post. Twenty-two articles were included, of which eight had TGNB participants only, two had mixed samples with separated outcome data for TGNB participants, and 12 had mixed samples with no disaggregated data. Experimental designs, participant samples, assessed variables, and type of interventions varied widely across studies, thus preventing comparisons. Overall results suggest improvements in psychological distress, depression, anxiety, suicidality, substance-related risk behaviors, coping skills/emotion regulation, stress appraisal, self-esteem, self-acceptance, social support, minority stress, resilience, hope, positive identity, and identity acceptance, although conclusions are limited by moderate-to-high risk of bias. Future research should implement more consistent and rigorous methodological designs to assess and compare intervention efficacy.
Human monkeypox outbreak: Epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study
Authors: Tristán Gabriel Sobral-Costas, Rafael Escudero-Tornero, Guillermo Servera-Negre, Jose I. Bernardino, Almudena Gutiérrez Arroyo, Marta Díaz-Menéndez, Jose Manuel Busto-Leis, Patricia Roces Álvarez, Pedro Herranz Pinto, Elena Sendagorta Cudos
Journal: Journal of the American Academy of Dermatology (2022)
Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses
Authors: Vincent Wai-Hin Yuen, David Kung-Chun Chiu, Cheuk-Ting Law, Jacinth Wing-Sum Cheu, Cerise Yuen-Ki Chan, Bowie Po-Yee Wong, Chi-Ching Goh, Misty Shuo Zhang, Helen Do-Gai Xue, Aki Pui-Wah Tse, Yan Zhang, Henry Yee-Hin Lau, Derek Lee, Rex K.H. Au-Yeung, Chun-Ming Wong, Carmen Chak-Lui Wong
Journal: Journal of Hepatology (2022)
Gabrb3 is required for the functional integration of pyramidal neuron subtypes in the somatosensory cortex
Authors: Rachel Babij, Camilo Ferrer, Alexander Donatelle, Sam Wacks, Amanda M. Buch, James E. Niemeyer, Hongtao Ma, Zhe Ran S. Duan, Robert N. Fetcho, Alicia Che, Takumi Otsuka, Theodore H. Schwartz, Ben S. Huang, Conor Liston, Natalia V. De Marco García
Journal: Neuron (2022)
Identification of redundancy between human <scp>FcεRIβ</scp> and <scp>MS4A6A</scp> proteins points toward additional complex mechanisms for <scp>FcεRI</scp> trafficking and signaling
Authors: Katie Bitting, Barry Hedgespeth, Lauren C. Ehrhardt‐Humbert, Greer K. Arthur, Alicia G. Schubert, Peter Bradding, Stephen L. Tilley, Glenn Cruse
Journal: Allergy (2022)

Allergic diseases are triggered by signaling through the high-affinity IgE receptor, FcεRI. In both mast cells (MCs) and basophils, FcεRI is a tetrameric receptor complex comprising a ligand-binding α subunit (FcεRIα), a tetraspan β subunit (FcεRIβ, MS4A2) responsible for trafficking and signal amplification, and a signal transducing dimer of single transmembrane γ subunits (FcεRIγ). However, FcεRI also exists as presumed trimeric complexes that lack FcεRIβ and are expressed on several cell types outside the MC and basophil lineages. Despite known differences between humans and mice in the presence of the trimeric FcεRI complex, questions remain as to how it traffics and whether it signals in the absence of FcεRIβ. We have previously reported that targeting FcεRIβ with exon-skipping oligonucleotides eliminates IgE-mediated degranulation in mouse MCs, but equivalent targeting in human MCs was not effective at reducing degranulation.
Ensuring equity in the era of HLA-restricted cancer therapeutics
Authors: James W Smithy, Amanda Blouin, Lisa C Diamond, Michael Postow
Journal: Journal for ImmunoTherapy of Cancer (2022)

In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele. This approval generated significant excitement, given the relative paucity of effective systemic therapies for advanced uveal melanoma. More broadly, tebentafusp represents the first T cell receptor agent to improve overall survival in any solid tumor. Although HLA-A*02:01 is the most common allele at this locus overall, its expression varies considerably among ethnic groups. It is most frequently expressed in Europeans, and less commonly in African Americans and people of Asian or Pacific Island ancestry. While uveal melanoma is most common in Caucasian populations, other HLA-restricted cancer therapeutics are being developed for indications with more diverse patient populations, such as cervical cancer. We advocate for proactive consideration of the populations eligible for each HLA-restricted therapeutic in development to ensure this emerging therapeutic class does not compound long-standing health disparities. As trials may focus on the most prevalent HLA subtypes, it will take the engagement of multiple stakeholders to ensure equitable access to patients of all ethnic backgrounds.
Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study
Authors: Chi-Yuan Yao, Andreas Agathangelidis, Shih-Sung Chuang, Hsiao-Hui Tsou, Wei-Lien Feng, Ta-Chih Liu, Tsai-Yun Chen, Yuan-Bin Yu, Su-Peng Yeh, Ming Yao, Chuan-Cheng Wang, Johnson Lin, Wen-Li Hwang, Jyh-Pyng Gau, Wen-Chien Chou, Tsu-Yi Chao, Liang-In Lin, Hwei-Fang Tien, Paolo Ghia, Shang-Ju Wu
Journal: HemaSphere (2022)

Asian patientswith chronic lymphocytic leukemia (CLL) exhibit immunoglobulin heavy variable (IGHV) gene repertoires that are distinct from those observed in Western populations, and a higher proportion of Asian CLL patients carry heavy loads of somatic hypermutations (SHM) within the B-cell receptor immunoglobulins (BcR IG). Due to the low regional incidence of CLL in Asia, only a limited number of studies had attempted to probe the phenomenon of BcR IG stereotypy in Asian populations. In this study, we analyzed the IGHV-IGHD-IGHJ gene rearrangements from a series of 255 CLL patients recruited in a nationwide, multicenter study in Taiwan. Our analysis revealed that the IGHV gene repertoire was characterized by evident biases, with IGHV3-7, IGHV4-34, and IGHV3-23 being the most frequent rearranged IGHV genes, and a higher proportion of cases carrying mutated IGHV. In terms of BcR stereotypy, the incidence of major subsets was less frequent in this cohort, with subsets #77 and #28A being the most common, while the incidence of minor subsets was approximately equivalent to that reported in the Western cohorts. With this study, we provide evidence that CLL in Asia is indeed associated with distinct immunogenetic characteristics regarding IGHV gene usage, SHM status, and BcR IG stereotypy.
2-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Annular Calcification, Rings, and Bioprostheses
Authors: Mackram F. Eleid, Dee Dee Wang, Amit Pursnani, Susheel K. Kodali, Issac George, Igor Palacios, Hyde Russell, Raj R. Makkar, Saibal Kar, Lowell F. Satler, Vivek Rajagopal, George Dangas, Gilbert H.L. Tang, James M. McCabe, Brian K. Whisenant, Kenith Fang, Tatiana Kaptzan, Bradley Lewis, Pamela Douglas, Rebecca Hahn, Jeremy Thaden, Jae K. Oh, Martin Leon, William O'Neill, Charanjit S. Rihal, Mayra E. Guerrero
Journal: Journal of the American College of Cardiology (2022)
Enhanced Mitochondrial Calcium Uptake Suppresses Atrial Fibrillation Associated With Metabolic Syndrome
Authors: Lucile Fossier, Mathieu Panel, Laura Butruille, Sarah Colombani, Lan Azria, Eloise Woitrain, Raphael Decoin, Angelo G. Torrente, Jérôme Thireau, Alain Lacampagne, David Montaigne, Jérémy Fauconnier
Journal: Journal of the American College of Cardiology (2022)
Noninvasive Plaque Imaging to Accelerate Coronary Artery Disease Drug Development
Authors: Gemma A. Figtree, Philip D. Adamson, Charalambos Antoniades, Roger S. Blumenthal, Michael Blaha, Matthew Budoff, David S. Celermajer, Mark Y. Chan, Clara K. Chow, Damini Dey, Girish Dwivedi, Nicola Giannotti, Stuart M. Grieve, Christian Hamilton-Craig, Bronwyn A. Kingwell, Jason C. Kovacic, James K. Min, David E. Newby, Sanjay Patel, Karlheinz Peter, Peter J. Psaltis, Stephen T. Vernon, Dennis T. Wong, Stephen J. Nicholls
Journal: Circulation (2022)

Coronary artery disease (CAD) remains the leading cause of adult mortality globally. Targeting known modifiable risk factors has had substantial benefit, but there remains a need for new approaches. Improvements in invasive and noninvasive imaging techniques have enabled an increasing recognition of distinct quantitative phenotypes of coronary atherosclerosis that are prognostically relevant. There are marked differences in plaque phenotype, from the high-risk, lipid-rich, thin-capped atheroma to the low-risk, quiescent, eccentric, nonobstructive calcified plaque. Such distinct phenotypes reflect different pathophysiologic pathways and are associated with different risks for acute ischemic events. Noninvasive coronary imaging techniques, such as computed tomography, positron emission tomography, and coronary magnetic resonance imaging, have major potential to accelerate cardiovascular drug development, which has been affected by the high costs and protracted timelines of cardiovascular outcome trials. This may be achieved through enrichment of high-risk phenotypes with higher event rates or as primary end points of drug efficacy, at least in phase 2 trials, in a manner historically performed through intravascular coronary imaging studies. Herein, we provide a comprehensive review of the current technology available and its application in clinical trials, including implications for sample size requirements, as well as potential limitations. In its effort to accelerate drug development, the US Food and Drug Administration has approved surrogate end points for 120 conditions, but not for CAD. There are robust data showing the beneficial effects of drugs, including statins, on CAD progression and plaque stabilization in a manner that correlates with established clinical end points of mortality and major adverse cardiovascular events. This, together with a clear mechanistic rationale for using imaging as a surrogate CAD end point, makes it timely for CAD imaging end points to be considered. We discuss the importance of global consensus on these imaging end points and protocols and partnership with regulatory bodies to build a more informed, sustainable staged pathway for novel therapies.
Maternal diet disrupts the placenta–brain axis in a sex-specific manner
Authors: Alexis M. Ceasrine, Benjamin A. Devlin, Jessica L. Bolton, Lauren A. Green, Young Chan Jo, Carolyn Huynh, Bailey Patrick, Kamryn Washington, Cristina L. Sanchez, Faith Joo, A. Brayan Campos-Salazar, Elana R. Lockshin, Cynthia Kuhn, Susan K. Murphy, Leigh Ann Simmons, Staci D. Bilbo
Journal: Nature Metabolism (2022)
Metabolon formation regulates branched-chain amino acid oxidation and homeostasis
Authors: McKenzie Patrick, Zhimin Gu, Gen Zhang, R. Max Wynn, Pranita Kaphle, Hui Cao, Hieu Vu, Feng Cai, Xiaofei Gao, Yuannyu Zhang, Mingyi Chen, Min Ni, David T. Chuang, Ralph J. DeBerardinis, Jian Xu
Journal: Nature Metabolism (2022)
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
Authors: Joana B. Pereira, Shorena Janelidze, Olof Strandberg, Christopher D. Whelan, Henrik Zetterberg, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson
Journal: Nature Aging (2022)

The role of microglia in tau accumulation is currently unclear but could provide an important insight into the mechanisms underlying Alzheimer's disease (AD)1. Here, we measured the microglial marker soluble TREM2 and the disease-associated microglial activation stage 2 markers AXL, MERTK, GAS6, LPL, CST7, SPP1 and CSF1 in nondemented individuals from the Swedish BioFINDER-2 cohort who underwent longitudinal tau-positron emission tomography (PET), amyloid-PET and global cognitive assessment. To assess whether baseline microglial markers had an effect on AD-related changes, we studied three sub-groups of individuals: 121 with evidence of amyloid-PET pathology (A+), 64 with additional evidence of tau-PET pathology (A+T+) and 159 without amyloid- or tau-PET pathology (A-T-). Our results showed that increased levels of TREM2 were associated with slower amyloid accumulation in A+ individuals in addition to slower tau deposition and cognitive decline in A+T+ subjects. Similarly, higher levels of AXL, MERTK, GAS6, LPL, CST7 and CSF1 predicted slower tau accumulation and/or cognitive decline in the A+T+ group. These findings have important implications for future therapeutic strategies aiming to boost microglial protective functions in AD.
Cognitive Assessment in Brazilian Adults with Sickle Cell Disease (SCD): The Burdens of Sociocultural Background and Correlations with Neuroimaging Findings
Authors: Pedro Junqueira Fleury Silva, Caroline Martins Silva, Brunno Machado de Campos, Paula De Melo Campos, Samuel de Souza Medina, Andreza Lamonica, Fernando Cendes, Fernando Ferreira Costa, Sara T Olalla Saad, Bruno Deltreggia Benites
Journal: Blood (2022)
Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Authors: Robin M. Hallett, Ester Bonfill-Teixidor, Raffaella Iurlaro, Alexandra Arias, Swetha Raman, Peter Bayliss, Olga Egorova, Almudena Neva-Alejo, AJ Robert McGray, Esther Lau, Alexandre Bosch, Melissa Beilschmidt, Dorothea Maetzel, Johan Fransson, Isabel Huber-Ruano, Judit Anido, Jean-Philippe Julien, Patricia Giblin, Joan Seoane
Journal: Clinical Cancer Research (2022)

Leukemia inhibitory factor (LIF) is a multifunctional cytokine with numerous reported roles in cancer and is thought to drive tumor development and progression. Characterization of LIF and clinical-stage LIF inhibitors would increase our understanding of LIF as a therapeutic target.We first tested the association of LIF expression with transcript signatures representing multiple processes regulating tumor development and progression. Next, we developed MSC-1, a high-affinity therapeutic antibody that potently inhibits LIF signaling and tested it in immune competent animal models of cancer.LIF was associated with signatures of tumor-associated macrophages (TAM) across 7,769 tumor samples spanning 22 solid tumor indications. In human tumors, LIF receptor was highly expressed within the macrophage compartment and LIF treatment drove macrophages to acquire immunosuppressive capacity. MSC-1 potently inhibited LIF signaling by binding an epitope that overlaps with the gp130 receptor binding site on LIF. MSC-1 showed monotherapy efficacy in vivo and drove TAMs to acquire antitumor and proinflammatory function in syngeneic colon cancer mouse models. Combining MSC-1 with anti-PD1 leads to strong antitumor response and a long-term tumor-free survival in a significant proportion of treated mice.Overall, our findings highlight LIF as a therapeutic target for cancer immunotherapy.
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
Authors: Monika Graeser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine zu Eulenburg, Ronald Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Journal: Clinical Cancer Research (2022)

Abstract Purpose: To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) and survival in the Phase II WSG-ADAPT HER2+/HR− trial (NCT01817452). Experimental Design: Patients with cT1-cT4c, cN0–3 HER2+/HR− early breast cancer (EBC) were randomized to pertuzumab+trastuzumab (P+T, n = 92) or P+T+paclitaxel (n = 42). Gene expression signatures were analyzed in baseline biopsies using NanoString Breast Cancer 360 panel (n = 117); baseline and on-treatment (week 3) sTIL levels were available in 119 and 76 patients, respectively. Impacts of standardized gene expression signatures on pCR and invasive disease-free survival (iDFS) were estimated by logistic and Cox regression. Results: In all patients, ERBB2 [OR, 1.70; 95% confidence interval (CI), 1.08–2.67] and estrogen receptor (ER) signaling (OR, 1.72; 95% CI, 1.13–2.61) were favorable, whereas PTEN (OR, 0.57; 95% CI, 0.38–0.87) was unfavorable for pCR. After 60 months median follow-up, 13 invasive events occurred (P+T: n = 11, P+T+paclitaxel: n = 2), none following pCR. Gene signatures related to immune response (IR) and ER signaling were favorable for iDFS, all with similar HR about 0.43–0.55. These patterns were even more prominent in the neoadjuvant chemotherapy-free group, where additionally BRCAness signature was unfavorable (HR, 2.00; 95% CI, 1.04–3.84). IR signatures were strongly intercorrelated. sTILs (baseline/week 3/change) were not associated with pCR or iDFS, though baseline sTILs correlated positively with IR signatures. Conclusions: Distinct gene signatures were associated with pCR versus iDFS in HER2+/HR− EBC. The potential role of IR in preventing recurrence suggests that patients with upregulated IR signatures could be candidates for de-escalation concepts in HER2+ EBC.
Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy
Authors: Xiaoqi Wang, Ruihao Huang, Wei Wu, Jingkang Xiong, Qin Wen, Yunjing Zeng, Ting Chen, Jiali Li, Cheng Zhang, Jiang F. Zhong, Shijie Yang, Xi Zhang
Journal: Blood (2022)
Trajectory of Blood Pressure in Pregnant People with Sickle Cell Disease: A Multinational Study
Authors: Macy L. Early, A. Kinga Malinowski, Marissa Solow, Ahizechukwu Eke, Nadine Shehata, Sana Saif Ur Rehman, Kevin H.M. Kuo, Lydia H. Pecker
Journal: Blood (2022)
Cervical Artery Lesions in Adults with Sickle Cell Disease : Are They Disease-Related ?
Authors: Nour Belkeziz, Marie-Pierre Gobin-Metteil, Corentin Provost, Suella Martino, Myriam Edjlali, Nicolas Mele, Benjamin Maïer, Anne Blanchet-Deverly, Jean-Benoit Arlet, Laure Joseph, Pablo Bartolucci, David Calvet
Journal: Blood (2022)
Preliminary Results of Promis Sexual Function and Satisfaction and Perceived Risk for Infertility after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Stellar Study
Authors: Lillian R Meacham, Anirudh Veludhandi, Yijin Xiang, Elizabeth Stenger, Staci D. Arnold, Akanksha Mehta, Lydia H. Pecker, Michael Hsieh, Jacqueline Y Maher, Lakshmanan Krishnamurti
Journal: Blood (2022)
Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood &amp; Marrow Transplant Research (CIBMTR)
Authors: Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda
Journal: Blood (2022)
Evaluation of Cost Drivers and Cost-Efficacy of Autologous Hematopoietic Transplant and Chimeric Antigen Receptor T-Cell Therapy in High-Grade B Cell Lymphoma from a Healthcare Firm Perspective
Authors: Ameet Patel, Jayant Bagai, Deidra A Dickerson, Kristen Muncy, Brittney M Baer, Nancy Long, Bipin Savani, Bhagirathbhai Dholaria, Burch Wood, Olalekan O. Oluwole
Journal: Blood (2022)
The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
Authors: Jennifer N. Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Shannon K. McWeeney, Stephen E. Kurtz, Guang Fan, Andy Kaempf, Karen McGovern, Lei Wang, Marta Sanchez-Martin, Dan S Kaufman, Evan F. Lind, Jeffrey W. Tyner
Journal: Blood (2022)